Skip to main content

Table 1 Univariate analysis of clinical factors and GPS for progression free survival (n = 402)

From: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

  Patients (%) mPFS months (95% CI) P-value
Age
<60 203 (50.5) 4.3 (3.8-4.7) 0.840
≥ 60 199 (49.5) 4.5 (3.9-5.1)  
Gender
Male 293 (72.9) 4.5 (3.9-5.0) 0.381
Female 109 (27.1) 4.3 (3.6-4.9)  
Liver Mets
Yes 125 (31.1) 4.1 (3.6-4.5) 0.243
No 277 (68.9) 4.6 (3.9-5.2)  
Peritoneal Mets
Yes 159 (39.6) 4.3 (3.8-4.8) 0.128
No 243 (60.4) 4.6 (3.9-5.2)  
Bone Mets
Yes 28 (7.0) 3.9 (2.4-5.3) 0.032
No 374 (93.0) 4.5 (4.0-5.0)  
Albumin
<3.5 77 (19.2) 3.4 (2.2-4.5) 0.013
≥ 3.5 325 (80.8) 4.6 (4.1-5.2)  
CRP
≤ 1 262 (65.1) 5.3 (4.5-6.0) 0.001
>1 140 (34.9) 3.4 (2.7-4.1)  
ECOG PS
0-1 329 (81.8) 4.6 (4.0-5.1) 0.002
≥ 2 73 (48.2) 3.0 (2.0-3.9)  
GPS
0 238 (59.2) 5.5 (4.8-6.2) 0.001
1 111 (27.6) 3.4 (2.7-4.1)  
2 53 (13.2) 3.3 (2.0-4.7)  
  1. mPFS: median progression free survival, Mets: Metastasis, CRP: C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow prognostic score